The U.S. Food and Drug Administration’s approval of Viz.ai’s hypertrophic cardiomyopathy establishes a new category for cardiovascular machine learning-based notification software.
WHY IT MATTERS
Viz.ai, a disease detection and intelligent care coordination company, said in its announcement…
Source: Healthcareitnews.com and Read More
The True Cost of Focusing on Cost Instead of Cost-Effectiveness
When payors consider only the cost of the medication and not the cost and risk to the patient, doctor, and healthcare system, the irony is
